Endocrine System Clinical Review: Pituitary, Thyroid,
Parathyroid & Adrenal Disorders | 2026/2027 Edition | 100
Verified Questions - 70 Questions with Answers
Endocrine System Clinical Review 2026-70 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100%
Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive study guide and test bank provides a rigorous review of endocrine disorders,
focusing on the pituitary, thyroid, parathyroid, and adrenal glands. With 100 verified questions, it is
designed to prepare nursing and medical students for clinical examinations and licensure tests. Each
question is accompanied by detailed rationales and evidence-based explanations, ensuring a deep
understanding of pathophysiology, clinical manifestations, diagnostic tests, and treatment modalities.
Updated for the 2026/2027 academic year, this resource aligns with current clinical guidelines and best
practices.
Key Features:
Anatomy and physiology of the endocrine system, including feedback mechanisms
Hypothalamic-pituitary axis and its regulatory role
Pituitary disorders: acromegaly, gigantism, diabetes insipidus, SIADH, hypopituitarism
Thyroid physiology and hormone synthesis
Hyperthyroidism and thyrotoxicosis (Graves' disease, toxic adenoma)
Hypothyroidism and myxedema coma
Thyroid nodules, goiter, and thyroid cancer
Parathyroid physiology and calcium regulation
Hyperparathyroidism and hypoparathyroidism
Adrenal cortex disorders: Cushing's syndrome, Addison's disease, adrenal insufficiency
Adrenal medulla disorders: pheochromocytoma
Pharmacological interventions and nursing management for endocrine disorders
Diagnostic tests, laboratory values, and imaging studies
Patient education and interprofessional care
Updates for 2026:
- Revised to reflect the latest Endocrine Society clinical practice guidelines
- Updated pharmacological management strategies, including new therapeutic agents
- Enhanced rationales with current evidence-based practice
- Incorporated recent research on genetic and molecular aspects of endocrine tumors
- Aligned with 2026/2027 NCLEX-RN and HESI test plan updates
Abstract:
This scholarly review presents a comprehensive examination of endocrine pathophysiology, emphasizing the
pituitary, thyroid, parathyroid, and adrenal glands. The content integrates foundational anatomy with advanced
clinical reasoning, covering hormonal regulation, feedback loops, and systemic effects. Each disorder is analyzed
through its etiology, clinical presentation, diagnostic criteria, and therapeutic interventions, with a focus on
nursing and medical management. The test bank includes 100 questions that challenge the learner to apply
knowledge in clinical scenarios, interpret laboratory data, and prioritize patient care. Rationales are provided to
reinforce key concepts and correct misconceptions. This guide serves as an essential tool for board examination
preparation and clinical practice, ensuring competency in managing patients with endocrine disorders.
Page 1
,Keywords:
Endocrine disorders, Pituitary disorders, Thyroid disorders, Parathyroid disorders, Adrenal disorders, Nursing
management, Clinical review, Test bank
Answer Format:
Each question is presented in multiple-choice format with four options. The correct answer is followed by a
detailed rationale explaining the underlying pathophysiology and clinical reasoning. Incorrect options are also
addressed to clarify common misconceptions, and relevant nursing implications are highlighted.
Compliance Checklist:
Aligned with 2026/2027 NCLEX-RN and HESI test plans
Evidence-based content from current clinical guidelines
100% verified answers with detailed rationales
Suitable for self-assessment and group study
Includes updates on pharmacological and non-pharmacological interventions
Content Area Overview:
Content Area Questions Key Topics Weight
Pituitary Disorders 1-25 Acromegaly, Gigantism, Diabetes Insipidus, 25%
SIADH, Hypopituitarism
Thyroid Disorders 26-50 Hyperthyroidism, Hypothyroidism, 25%
Thyroiditis, Goiter, Thyroid Cancer
Parathyroid Disorders 51-65 Hyperparathyroidism, Hypoparathyroidism, 15%
Calcium Regulation, Bone Disorders
Adrenal Disorders 66-90 Cushing's Syndrome, Addison's Disease, 25%
Adrenal Insufficiency, Pheochromocytoma
Pharmacology and Nursing 91-100 Hormone Replacement, Antithyroid Agents, 10%
Management Corticosteroids, Patient Education
Page 2
,Q1. In a patient with confirmed Cushing disease, bilateral inferior petrosal sinus
sampling (IPSS) demonstrates a central-to-peripheral ACTH ratio of 1.5 before and
2.0 after CRH administration. Which additional finding would most strongly indicate
the presence of a pituitary microadenoma amenable to selective adenomectomy?
A. A gradient between the two petrosal sinuses of 1.4 after CRH
B. Visible 6-mm hypoenhancing lesion on sellar MRI
C. Suppression of serum cortisol to <1.8 mcg/dL after 1 mg overnight dexamethasone
D. Elevated urinary free cortisol >3 times the upper limit of normal
Correct Answer: A. A gradient between the two petrosal sinuses of 1.4 after CRH
Rationale: In IPSS, a post-CRH interpetrosal sinus ACTH gradient "e1.4 lateralizes the
microadenoma, guiding surgical resection. A visible lesion on MRI is helpful but may be
absent in up to 50% of microadenomas. Suppression with dexamethasone and elevated
UFC confirm the diagnosis of Cushing disease but do not localize the tumor.
Why Wrong:
B - MRI may be negative in many microadenomas; a visible lesion is not required and
does not confirm lateralization.
C - This finding supports the diagnosis of Cushing syndrome but does not provide
lateralizing information.
D - Elevated UFC is a diagnostic criterion but does not localize the adenoma.
Reference: Williams Textbook of Endocrinology, 14th ed., Ch. 9; Endocrine Society
Clinical Practice Guideline for Cushing's Syndrome, 2008/2020.
Q2. A patient with profound fatigue and weight gain is found to have a serum TSH of
0.01 mIU/L and free T4 of 0.4 ng/dL. Which additional finding would best distinguish
central hypothyroidism from nonthyroidal illness?
A. Low 24-hour urinary free cortisol
B. Elevated serum reverse T3
C. Normal or elevated serum prolactin
D. Blunted TSH response to TRH stimulation
Correct Answer: C. Normal or elevated serum prolactin
Rationale: Central hypothyroidism often coexists with hyperprolactinemia due to a
pituitary mass or stalk compression; this is a specific clue. Low cortisol may indicate
concomitant ACTH deficiency but is not specific. Elevated reverse T3 suggests
nonthyroidal illness. Blunted TSH response occurs in both central hypothyroidism and
some cases of NTI, limiting its utility.
Why Wrong:
A - Low cortisol can occur in both central hypoadrenalism and critical illness, not
distinguishing.
B - Elevated reverse T3 is characteristic of nonthyroidal illness, not central
Page 3
, hypothyroidism.
D - TSH response to TRH is often blunted in both central hypothyroidism and NTI, so
it does not reliably differentiate.
Reference: Larsen, Williams Textbook of Endocrinology, 14th ed., Ch. 10; ATA guidelines
on hypothyroidism.
Q3. Following total thyroidectomy for medullary thyroid carcinoma, a patient has
undetectable calcitonin and normal CEA. However, germline testing reveals a RET
codon 918 mutation. What is the most appropriate clinical recommendation
regarding biochemical surveillance?
A. Measure calcitonin and CEA every 6 months for life, with imaging only if levels
rise
B. Discontinue routine calcitonin monitoring and follow with annual neck ultrasound
alone
C. Perform routine imaging (CT chest/abdomen) every 6 months regardless of
calcitonin levels
D. Repeat germline testing for a different mutation before changing surveillance
Correct Answer: A. Measure calcitonin and CEA every 6 months for life, with
imaging only if levels rise
Rationale: RET M918T (codon 918) is associated with multiple endocrine neoplasia type
2B and a high risk of persistent or recurrent medullary thyroid carcinoma. Even with
undetectable calcitonin, lifelong surveillance is warranted because recurrence can occur.
Imaging is reserved for when biochemical markers rise. CEA should also be monitored.
Why Wrong:
B - Discontinuing calcitonin monitoring is unsafe given the high-risk RET mutation.
C - Routine imaging without biochemical evidence of recurrence is not recommended.
D - The RET M918T mutation is well-established; repeat testing is unnecessary.
Reference: ATA Guidelines for Medullary Thyroid Carcinoma, 2015; NCCN Guidelines
for Thyroid Carcinoma, 2026.
Q4. A patient with primary hyperparathyroidism has a serum calcium of 11.2 mg/dL,
PTH of 85 pg/mL (normal 10-65), and 24-hour urine calcium of 420 mg. Sestamibi
imaging is negative. Which of the following findings would most strongly suggest the
presence of a parathyroid carcinoma rather than an adenoma?
A. Presence of a palpable neck mass and a serum calcium >14 mg/dL
B. Concurrent vitamin D deficiency (25-OHD 12 ng/mL)
C. Absence of nephrolithiasis despite hypercalciuria
D. Family history of hyperparathyroidism-jaw tumor syndrome
Correct Answer: A. Presence of a palpable neck mass and a serum calcium >14
Page 4
Parathyroid & Adrenal Disorders | 2026/2027 Edition | 100
Verified Questions - 70 Questions with Answers
Endocrine System Clinical Review 2026-70 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100%
Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive study guide and test bank provides a rigorous review of endocrine disorders,
focusing on the pituitary, thyroid, parathyroid, and adrenal glands. With 100 verified questions, it is
designed to prepare nursing and medical students for clinical examinations and licensure tests. Each
question is accompanied by detailed rationales and evidence-based explanations, ensuring a deep
understanding of pathophysiology, clinical manifestations, diagnostic tests, and treatment modalities.
Updated for the 2026/2027 academic year, this resource aligns with current clinical guidelines and best
practices.
Key Features:
Anatomy and physiology of the endocrine system, including feedback mechanisms
Hypothalamic-pituitary axis and its regulatory role
Pituitary disorders: acromegaly, gigantism, diabetes insipidus, SIADH, hypopituitarism
Thyroid physiology and hormone synthesis
Hyperthyroidism and thyrotoxicosis (Graves' disease, toxic adenoma)
Hypothyroidism and myxedema coma
Thyroid nodules, goiter, and thyroid cancer
Parathyroid physiology and calcium regulation
Hyperparathyroidism and hypoparathyroidism
Adrenal cortex disorders: Cushing's syndrome, Addison's disease, adrenal insufficiency
Adrenal medulla disorders: pheochromocytoma
Pharmacological interventions and nursing management for endocrine disorders
Diagnostic tests, laboratory values, and imaging studies
Patient education and interprofessional care
Updates for 2026:
- Revised to reflect the latest Endocrine Society clinical practice guidelines
- Updated pharmacological management strategies, including new therapeutic agents
- Enhanced rationales with current evidence-based practice
- Incorporated recent research on genetic and molecular aspects of endocrine tumors
- Aligned with 2026/2027 NCLEX-RN and HESI test plan updates
Abstract:
This scholarly review presents a comprehensive examination of endocrine pathophysiology, emphasizing the
pituitary, thyroid, parathyroid, and adrenal glands. The content integrates foundational anatomy with advanced
clinical reasoning, covering hormonal regulation, feedback loops, and systemic effects. Each disorder is analyzed
through its etiology, clinical presentation, diagnostic criteria, and therapeutic interventions, with a focus on
nursing and medical management. The test bank includes 100 questions that challenge the learner to apply
knowledge in clinical scenarios, interpret laboratory data, and prioritize patient care. Rationales are provided to
reinforce key concepts and correct misconceptions. This guide serves as an essential tool for board examination
preparation and clinical practice, ensuring competency in managing patients with endocrine disorders.
Page 1
,Keywords:
Endocrine disorders, Pituitary disorders, Thyroid disorders, Parathyroid disorders, Adrenal disorders, Nursing
management, Clinical review, Test bank
Answer Format:
Each question is presented in multiple-choice format with four options. The correct answer is followed by a
detailed rationale explaining the underlying pathophysiology and clinical reasoning. Incorrect options are also
addressed to clarify common misconceptions, and relevant nursing implications are highlighted.
Compliance Checklist:
Aligned with 2026/2027 NCLEX-RN and HESI test plans
Evidence-based content from current clinical guidelines
100% verified answers with detailed rationales
Suitable for self-assessment and group study
Includes updates on pharmacological and non-pharmacological interventions
Content Area Overview:
Content Area Questions Key Topics Weight
Pituitary Disorders 1-25 Acromegaly, Gigantism, Diabetes Insipidus, 25%
SIADH, Hypopituitarism
Thyroid Disorders 26-50 Hyperthyroidism, Hypothyroidism, 25%
Thyroiditis, Goiter, Thyroid Cancer
Parathyroid Disorders 51-65 Hyperparathyroidism, Hypoparathyroidism, 15%
Calcium Regulation, Bone Disorders
Adrenal Disorders 66-90 Cushing's Syndrome, Addison's Disease, 25%
Adrenal Insufficiency, Pheochromocytoma
Pharmacology and Nursing 91-100 Hormone Replacement, Antithyroid Agents, 10%
Management Corticosteroids, Patient Education
Page 2
,Q1. In a patient with confirmed Cushing disease, bilateral inferior petrosal sinus
sampling (IPSS) demonstrates a central-to-peripheral ACTH ratio of 1.5 before and
2.0 after CRH administration. Which additional finding would most strongly indicate
the presence of a pituitary microadenoma amenable to selective adenomectomy?
A. A gradient between the two petrosal sinuses of 1.4 after CRH
B. Visible 6-mm hypoenhancing lesion on sellar MRI
C. Suppression of serum cortisol to <1.8 mcg/dL after 1 mg overnight dexamethasone
D. Elevated urinary free cortisol >3 times the upper limit of normal
Correct Answer: A. A gradient between the two petrosal sinuses of 1.4 after CRH
Rationale: In IPSS, a post-CRH interpetrosal sinus ACTH gradient "e1.4 lateralizes the
microadenoma, guiding surgical resection. A visible lesion on MRI is helpful but may be
absent in up to 50% of microadenomas. Suppression with dexamethasone and elevated
UFC confirm the diagnosis of Cushing disease but do not localize the tumor.
Why Wrong:
B - MRI may be negative in many microadenomas; a visible lesion is not required and
does not confirm lateralization.
C - This finding supports the diagnosis of Cushing syndrome but does not provide
lateralizing information.
D - Elevated UFC is a diagnostic criterion but does not localize the adenoma.
Reference: Williams Textbook of Endocrinology, 14th ed., Ch. 9; Endocrine Society
Clinical Practice Guideline for Cushing's Syndrome, 2008/2020.
Q2. A patient with profound fatigue and weight gain is found to have a serum TSH of
0.01 mIU/L and free T4 of 0.4 ng/dL. Which additional finding would best distinguish
central hypothyroidism from nonthyroidal illness?
A. Low 24-hour urinary free cortisol
B. Elevated serum reverse T3
C. Normal or elevated serum prolactin
D. Blunted TSH response to TRH stimulation
Correct Answer: C. Normal or elevated serum prolactin
Rationale: Central hypothyroidism often coexists with hyperprolactinemia due to a
pituitary mass or stalk compression; this is a specific clue. Low cortisol may indicate
concomitant ACTH deficiency but is not specific. Elevated reverse T3 suggests
nonthyroidal illness. Blunted TSH response occurs in both central hypothyroidism and
some cases of NTI, limiting its utility.
Why Wrong:
A - Low cortisol can occur in both central hypoadrenalism and critical illness, not
distinguishing.
B - Elevated reverse T3 is characteristic of nonthyroidal illness, not central
Page 3
, hypothyroidism.
D - TSH response to TRH is often blunted in both central hypothyroidism and NTI, so
it does not reliably differentiate.
Reference: Larsen, Williams Textbook of Endocrinology, 14th ed., Ch. 10; ATA guidelines
on hypothyroidism.
Q3. Following total thyroidectomy for medullary thyroid carcinoma, a patient has
undetectable calcitonin and normal CEA. However, germline testing reveals a RET
codon 918 mutation. What is the most appropriate clinical recommendation
regarding biochemical surveillance?
A. Measure calcitonin and CEA every 6 months for life, with imaging only if levels
rise
B. Discontinue routine calcitonin monitoring and follow with annual neck ultrasound
alone
C. Perform routine imaging (CT chest/abdomen) every 6 months regardless of
calcitonin levels
D. Repeat germline testing for a different mutation before changing surveillance
Correct Answer: A. Measure calcitonin and CEA every 6 months for life, with
imaging only if levels rise
Rationale: RET M918T (codon 918) is associated with multiple endocrine neoplasia type
2B and a high risk of persistent or recurrent medullary thyroid carcinoma. Even with
undetectable calcitonin, lifelong surveillance is warranted because recurrence can occur.
Imaging is reserved for when biochemical markers rise. CEA should also be monitored.
Why Wrong:
B - Discontinuing calcitonin monitoring is unsafe given the high-risk RET mutation.
C - Routine imaging without biochemical evidence of recurrence is not recommended.
D - The RET M918T mutation is well-established; repeat testing is unnecessary.
Reference: ATA Guidelines for Medullary Thyroid Carcinoma, 2015; NCCN Guidelines
for Thyroid Carcinoma, 2026.
Q4. A patient with primary hyperparathyroidism has a serum calcium of 11.2 mg/dL,
PTH of 85 pg/mL (normal 10-65), and 24-hour urine calcium of 420 mg. Sestamibi
imaging is negative. Which of the following findings would most strongly suggest the
presence of a parathyroid carcinoma rather than an adenoma?
A. Presence of a palpable neck mass and a serum calcium >14 mg/dL
B. Concurrent vitamin D deficiency (25-OHD 12 ng/mL)
C. Absence of nephrolithiasis despite hypercalciuria
D. Family history of hyperparathyroidism-jaw tumor syndrome
Correct Answer: A. Presence of a palpable neck mass and a serum calcium >14
Page 4
